Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Bristol-Myers Squibb
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Male or female participants with a confirmed diagnosis of the specific subtypes of peripheral T-cell lymphoma (PTCL) according to The World Health Organization (WHO) classification of lymphoid neoplasm, 4th edition defined by WHO and International Agency for Research on Cancer (IARC).
Participates aged ≥18 years of age at diagnosis of PTCL.
Participates who have been treated with a systemic therapy for PTCL and have initiated a systemic therapy as a second-line therapy for relapsed or refractory PTCL between April 1, 2018 and March 31, 2023.
You may not be if
Participates who have medical history of peripheral T-cell lymphoma (PTCL) treatment by unapproved drug in Japan as of 31 March 2024 or off-label drug for PTCL in Japan as of 31 March 2024.
Participates who have medical history of participation to a separately defined registration study for regulatory approval in PTCL.
Participates who have medical history of PTCL treatment in a separately defined clinical study with intervention by on-label regimen for PTCL.
Participates judged to be inappropriate for enrollment in this study by the site investigator.
Clareo Health | Observational Study in Japanese Patients With Peripheral T-Cell Lymphoma Who Received Second-Line Therapy
